Codon-specific KRAS mutations predict survival in advanced pancreatic cancer

A. Boilève, A. Rousseau,M. Hilmi, A. Tarabay,J.R.R. Mathieu,J. Cartry, S. Bedja, N. Goudarzi,C. Nicotra,M. Ngo-Camus, V. Boige,M. Valéry, T. Pudlarz,M.-A. Bani, P. Dartigues,L. Tselikas,A. Italiano, S. Cosconea, M. Gelli, E. Fernandez-de-Sevilla

ESMO Gastrointestinal Oncology（2024）

引用 0|浏览3

暂无评分

摘要

•KRAS mutations in PDAC have distinct impacts on tumor initiation and outcomes.•This study compared characteristics and outcomes of PDAC based on codon-specific KRAS mutants (G12 versus others).•No significant differences in main characteristics, except for BRAF, were observed between KRASG12 and KRASother.•KRASG12 patients had worse overall survival compared to KRASother patients in PDAC, but similar response to treatments.•This study indicates the importance of codon-specific KRAS mutations in prognosis.

查看译文

关键词

precision medicine,KRAS,pancreatic cancer

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要